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Summary. In previous studies we evaluated the incidence 
and specificity of autologous antibody reactivity against 
squamous cell carcinoma of the head and neck (SCCHN). 
We were able to demonstrate that autologous antibody 
reactivity is present in native sera but was usually of too 
low a titer to allow further analysis. Dissociation of im- 
mune complexes by acidification and ultrafiltration of se- 
rum augmented autologous antibody reactivity in nine out 
of nine autologous systems tested. Native antibody and 
antibody derived from immune complexes produced by the 
host and reactive with autologous tumor cells may be 
directed against physiologically relevant antigens. There- 
fore, correlations of antibody titers with clinical course 
may provide insight into the nature of the host response to 
cancer. In the present analysis, serological studies of 
six patients with SCCHN were performed with serum 
samples obtained over many months. Results of serial sero- 
logical assays were correlated to tumor progression and 
clinical course. Fluctuations in autologous antibody reac- 
tivity were noted over time. In four cases, rises in autolo- 
gous antibody titers preceded the clinical diagnosis of re- 
currence by several months. Drops in autologous antibody 
reactivity were noted in two cases following surgery or 
radiation therapy. In two cases of long-term survivors, no 
correlation between antibody reactivity and clinical course 
was noted. Specificity analysis of the six autologous sys- 
tems demonstrated reactivity against autologous and allo- 
geneic SCCHN as well as melanoma cell lines. These sera 
did not react with glioma, neuroblastoma, renal cell, breast, 
bladder and colon carcinoma cell lines nor with fetal calf 
serum, pooled lymphocytes, red blood cells and platelets. 
Autologous serial serological studies may provide a means 
by which to evaluate the host/tumor relationship in patients 
with SCCHN. 
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Introduction 
The definition and characterization of tumor-associated 
antigens has been a major focus of tumor immunology for 
over two decades. Detection of these antigens has relied 
upon polyclonal xenogeneic and allogeneic antisera and 
more recently, murine monoclonal antibodies [7, 8, 12]. 
The majority of these investigations have been on melano- 
ma and other tumors and there have been only a limited 
number of studies involving squamous cell carcinoma of 
the head and neck (SCCHN). As with other malignant 
diseases, monoclonal antibodies directed against SCCHN 
have been developed [6, 9, 10]; however, none has been 
shown to be absolutely restricted to tumor cells. An alter- 
native approach to utilizing heteroantisera is to study the 
nature of the antibody response produced by the host. By 
doing so it may be possible to detect antigens not apparent 
to heteroantisera or monoclonal antibodies. 
In previous work we examined the incidence and speci- 
ficity of autologous antibodies in patients with melanoma 
[3, 11] and SCCHN [4, 23]. As has been reported by others, 
these antibodies are usually of low incidence and titer. We 
demonstrated that, in a method described by Sjogren et al. 
[18], dissociation of immune complexes in melanoma and 
SCCHN [11, 23] augments autologous antibody reactivity 
in the majority of cases studied. Further studies in melano- 
ma have shown correlations between autologous antibody 
titers, clinical course and prognosis [19-21].  In SCCHN 
native sera from eight patients were subjected to acid dis- 
sociation and ultrafiltration of sera. Prior to this, sera from 
only four of these patients were noted to have antibody 
reactivity against cultured autologous SCCHN cells as 
tested by protein A hemadsorption. After acid dissocia- 
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tion/ultrafiltration, sera from all eight patients demon-  
strated enhanced IgG reactivity against SCCHN. 
We  have now extended out  work in SCCHN to explore 
further the relationship between autologous immuni ty  and 
the natural  history of the disease. One way to pursue this is 
through serial studies of individual  patients. Serial studies 
offer a unique means by which the correlations between 
clinical course and autologous antibody reactivity may be 
evaluated. By examining  patients '  sera at different times it 
may be possible to detect transient changes in ant ibody 
titer that are associated with the inception of recurrent 
disease or response to therapy. This paper represents the 
first study to explore the relationship between autologous 
ant ibody reactivity and clinical course in patients with 
squamous cell carcinoma. We  report our f indings in six 
patients with SCCHN followed over the course of their 
disease. 
Materials and methods 
Cell lines 
Absorption analysis. Absorptions were performed using a wide range of 
fresh, cryopreserved and cultured heterologous, allogeneic, and autolo- 
gous cells. These were washed three times and for qualitative absorpüons 
mixed at 1 : 1 v/v (1 x 108 cells/ml minimum) with the serum to be tested 
(0.1 ml, at a serum dilution two doublings below the endpoint of the 
titration for that serum). Absorptions were carried out for 30 min at 4 ° C 
then 30 min at 37 ° C. Specimens were then centrifuged at 2000 rpm for 
20 min in a Sorvall RC3B refrigerated centrifuge. Supernätant serum was 
retested with an aliquot of control unabsorbed serum incubated in paral- 
lel, using protein A hemadsorption to assess the degree of specific 
antibody absorption. 
Immune complex dissociation 
The method, initially described by Sjogren et al. [18], was used to 
dissociate immune complexes. Briefly, a 60-ml ultrafiltration chamber 
and Amicon HP-30 membrane (Amicon Corporation, Danvers, Mass.) 
were used. A sample of 2-3 ml prefiltered (0.45 gm, Millipore) serum 
was added to 50 ml glycine/saline buffer, 0.1 M, pH 3.1, in the ultrafiltra- 
tion chamber. Ultrafiltration was performed at 4 ° C under 69 kPa (10 lb 
in -2) N2 until the original volume of the test solution was reached. This 
was repeated twice and the sample was then washed three times with 
50 ml PBS, and concentrated to the original volume of serum. The total 
time involved varied from 24 h to 48 h depending upon the serum used. 
SCCHN ceU lines. The method described by Krause et al. [13] was 
developed in our laboratory for establishing SCCHN cell lines. 
Squamous cell carcinoma lines UM-SCC-8, -9, -17, -21, -30, and -36 
were all derived from patients treated and followed in the Departments of 
Otolaryngology and Dermatology at the University of Michigan. The 
clinical course of each patient and the type of specimen used to establish 
each cell line is given in Results. 
Non-SCCHN cell lines. Acquisition and maintenance of non-SCCHN 
cell lines have been previously reported [ 11 ]. For specificity analysis the 
following additional cell lines were used: melanoma cell lines Y-Mel 
84 : 420 an Y-Mel 81:710 provided by Dr. John Kirkwood (University of 
Pittsburgh), neuroblastoma cell line SK-N-MC, glioma ceU line and 
LN-18, fetal fibroblast cell line FF-110 supplied by Dr. Theresa 
Whiteside (University of Pittsburgh), and renal cell carcinoma cell lines 
630D and IGR3 supplied by Dr. Byron Ballou (University of Pittsburgh); 
bladder carcinoma cell line HTB4 was kindly provided by Dr. Craig 
McCune (University of Rochester, School of Medicine, Rochester, 
N. Y.). 
Serological methods 
All patients participating in this study consented to provide serial serum 
specimens during clinic or hospital visits. Aliquots of serum were stored 
at-70°C. 
Protein A hemadsorption. The protein A hemadsorption assay was per- 
formed after the method described by Pfreundschuh et al. [15]. Briefly, 
indicator cells for the protein A mixed hemadsorption tests were prepared 
by conjugating staphylococcal protein A (Pharmacia Fine Chemicals) to 
the surface of selected human blood group 0 Rh-positive red blood cells 
with 0.01% CrC13 at pH 5.0. Indicator cells were washed twice in 
phosphate-buffered saline (PBS) plus 1% immunoglobulin-free fetal calf 
serum (Ig-free FCS) (Gibco) and resuspended for use in this medium. 
Target monolayers were seeded in micro-Terasaki assay plates and incu- 
bated with serial dilutions of autologous sera. After incubation of target 
cells with sera at 37 ° C, wells were washed three times with PBS contain- 
ing 2% Ig-free FCS at 37°C and 0.01 ml 0.15% suspension of indicator 
cells was added to each well. Plates were washed two to four times with 
PBS/2% Ig-free FCS after 45 min, and positive cells defined as those 
with a >50% erythrocyte rosette. The endpoint of the assay was the last 
well with 10% of positive target cells. All assays were performed in 
duplicate. 
Results 
Immune complex dissociation of  sera 
Our f indings with eight autologous systems (UM-SCC-9,  
-17, -21, -23, -24, -30, -35, and -36) have previously been 
reported [23]. Serum from the patient from whom UM- 
SCC-8 was obtained demonstrated a rise in autologous 
antibody titer from 1 : 32 in native serum to 1 : 2048 follow- 
ing i m m u n e  complex dissociation. 
Specificity analysis 
To determine the distr ibution of expression of the antigens 
detected by autologous antibodies specificity analysis was 
performed against a variety mal ignant  and non-mal ignan t  
cells. Because of the l imited amount  of sera available all 
specificity analyses were performed with immune-com-  
plex-dissociated sera using a single high-titer serum. The 
results are summarized in Table 1. A similar fange of 
reactivity was noted in all six autologous systems. In each 
case autologous antibody was absorbed by all seven 
SCCHN cell lines and two melanoma cell lines. No reactiv- 
ity was noted against neuroblastoma,  glioma, renal cell 
carcinoma, bladder carc inoma and colon carcinoma cell 
lines. In addition, no reactivity was noted against fetal 
fibroblasts, fetal calf  serum, pooled lymphocytes,  red 
blood cells and platelets. 
Serial autologous studies 
Serial studies were performed on six autologous systems 
(UM-SCC-8,  -9, -17, -21, -30, and -36). Sera obtained at 
mult iple intervals were tested before and after immune  
complex dissociation against autologous SCCHN by pro- 
tein A hemadsorption. These results are shown in 
Figs. 1 - 6 .  The fiter of  ant ibody reactivity in serum speci- 
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Table 1. Distribution of antigens defined by autologous antibody to squamous cell carcinomas of the head and neck a 
Target cell line a Autologous system a 
Um-SCC-8 UM-SCC-9 U M - S C C - 1 7  U M - S C C - 2 1  UM-SCC-30 UM-SCC-36 
Squamus cell carcinoma 
UM-SCC-8 + + + + + + 
UM-SCC-9 + + + + + + 
UM-SCC-17 + + + + + + 
UM-SCC-21 + + + + + + 
UM-SCC-30 + + + + + + 
UM-SCC-35 + + + + + + 
UM-SCC-36 + + + + + + 
Melanoma 
Y-MEL 84: 420 + + + + + + 
Y-MEL 81:710 + + + + + + 
Neuroblastoma 
SK-N-MC 0 0 0 0 0 0 
Glioma 
LN-18 0 0 0 0 0 0 
Renal cell carcinoma 
630D 0 0 0 0 0 0 
IGR3 0 0 0 0 0 0 
Breast carcinoma 
MCF-7 0 0 0 0 0 0 
Bladder carcinoma 
HTB4 0 0 0 0 0 0 
Colon carcinoma 
HCT-8 0 0 0 0 0 0 
Fetal fibroblasts 
FF-110 0 0 0 0 0 0 
Fetal calf serum 0 0 0 0 0 0 
Pooled lymphocytes 0 0 0 0 0 0 
Pooled red blood cells 0 0 0 0 0 0 
Pooled platelets 0 0 0 0 0 0 
a Sera from each autologous system were tested against the cells shown in this column both directly with protein A hemadsorption and by absorption 
with those cells and subsequent testing back against the appropriate autologous tumor cell line. +, Cross-reactivity of the autologous antibody with that 
cell line; 0, no reactivity 
mens taken at different times during the clinical course of 
these patients was correlated with clinical status. Ant ibody  
reactivity in separate sera varied in fiter before and after 
acid immune  complex dissociation. 
Autologous system UM-SCC-8. Serial serum samples were 
obtained from the t ime of first treatment of this 70-year-old 
woman  with leukoplakia and a T1NOM0 squamous cell 
carcinoma (SCC) of the left buccal  mucosa.  In  the 
6 months fol lowing the primary surgical excision, the 
patient had several persistent areas of leukoplakia and 
squamous papil loma, which were biopsied and found to 
have no tumor. However,  an increase in ant ibody titers was 
noted in both native and immune-complex-dissocia ted  sera 
(Fig. 1). This correlated with the development  of a sub- 
mandibular  mass which, fol lowing resection, was felt to be 
a benign condition, sialoadenitis. In retrospect, however,  
there may have been tumor occluding the salivary duct that 
led to this condit ion because when the patient did develop 
clinically documented recurrent disease it was found in the 
left floor of the mouth near the opening of the duct. Anti-  
body titers subsequently fell, only to rise again prior to 
histologically confirmed tumor recurrence of the pat ient '  s 
SCCHN in a lesion in the anterior floor of the mouth. The 
patient was treated with surgical excision, external-beam 
radiotherapy and a ces ium implant.  Persistent disease in- 
volving the mandible  necessitated further surgery. It was 
from this last operative procedure that the UM-SCC-8  
tumor cell l ine was established. Autologous ant ibody titers 
fell after these interventions.  Unfor tunate ly  the patient died 
as a result of  a post-operative sepsis. The second rise in 
autologous ant ibody titers corresponded to the disease re- 
currence. The first rise in autologous antibody titers was 
not associated with proven disease recurrence unless there 
was occult SCCHN removed with the salivary gland resec- 
t ion that was not appreciated at the t ime of surgery. 
Autologous system UM-SCC-9. This 72-year-old woman  
inifially had a T2NOM0 SCC of the left side of the tongue 
that was treated with a partial glossectomy, radical neck 
dissection and radiation therapy 3 years prior to this study. 
Serial serum specimens were collected 1 month  fol lowing 
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Fig. 1. Clinical time course for autologous 
system UM-SCC-8. The changes in autolo- 
gous antibody titer according to the clinical 
time course of the patient who was the donor 
of UM-SCC-8. B ,  Native serum antibody 
titers; +, immune complex dissociated serum 
antibody titers 
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Fig. 2. Clinical time course for autologous 
system UM-SCC-9. The changes in autolo- 
gous antibody titer according to the clinical 
time course of the patient who was the donor 
of UM-SCC-9. B,  Native serum antibody 
titers; +, immune complex dissociated serum 
antibody titers 
resection of recurrent cancer of the floor of mouth (Fig. 2). 
She later developed an in situ cancer of the tongue. Follow- 
ing surgical resection of these tumors a rise in autologous 
antibody reactivity was noted, first only in sera treated by 
acid dissociation/ultrafiltration and detected 5 months later 
in native sera as well. These increases in autologous anti- 
body titers preceded clinical evidence of disease recurrence 
in the tongue and neck (Fig. 2). Surgical resection con- 
sisting of a further partial glossectomy and radical neck 
dissection was performed and the UM-SCC-9 cell line was 
established. Following this surgery both native and im- 
mune complex dissociated titers began to rise again, pre- 
ceding the development of a local recurrence and metasta- 
sis. 
Autologous system UM-SCC-17. This 48-year-old woman 
initially presented with a T1NOM0 SCC of the left true 
vocal cord. She was treated with radiation but at the com- 
pletion of her therapy was noted to have persistent disease 
and subsequently underwent a total laryngectomy and radi- 
cal dissection of the left side of the neck. The UM-SCC-17 
cell line was established from the primary tumor specimen 
[5]. Serial serum samples were obtained starting with the 
follow-up visits after surgery. Autologous antibody titers 
in native and immune complex dissociated sera were high 
for 20 months, fell over a 4-month interval and then began 
to rise gradually over the following year and a half. There 
were no changes in her clinical status during this time and 
she has remained free of disease to the present time, a 
period of more than 8.5 years (Fig. 3). 
Autologous system UM-SCC-21. Twelve years after treat- 
ment of a basal cell carcinoma of the nasal dorsum this 
65-year-old man presented with SCC of the nose, eyelid 
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Fig. 3. Clinical time course for autologous 
system UM-SCC-17. The changes in autolo- 
gous antibody titer according to the clinical 
time course of the patient who was the donor 
of UM-SCC-17. m, Native serum antibody 
titers; +, immune complex dissociated serum 
antibody titers. NED, no evidence of disease 
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Fig. 4. Clinical time course for autologous system UM-SCC-21. The 
changes in autologous antibody titer according to the clinical time course 
of the patient who was the donor of UM-SCC-21. B, Native serum 
antibody titers; +, immune complex dissociated serum antibody titers 
and right medial canthus. The lesion required resection of 
the ethmoid bone and a skin graft followed by radiother- 
apy. He subsequently developed a local recurrence in the 
ethmoid sinus. This was resected with a right radical eth- 
moidectomy. The UM-SCC-21A cell line was established 
from this specimen and was used to test the sera. A recur- 
rent tumor was resected from the superior aspect of  the 
resection site 4 months later. Serial serum specimens were 
obtained starting at that point (Fig. 4). He was clinically 
free of disease for 14 months until a mass positive for SCC 
developed in the left side of the neck, which was resected 
and radiated. He remained clinically free of  disease for 
10 months until he developed a pathological fracture of  the 
right humerus, which was treated with surgical excision 
and interual fixation. The patient's disease continued to 
progress slowly with spread of his tumor to the con- 
tralateral ethmoid sinus and medial canthus 4 and 9 months 
later respectively. The patient continued to develop addi- 
tional distant metastases over the next 3 years and he died 
of progressive disease 5 years after the diagnosis of SCC. 
Antibody titers in immune complex dissociated sera were 
elevated during most of  his clinical course. Two drops in 
autologous antibody titers were noted, one following treat- 
ment of his neck mass and the second following the left 
ethmoidectomy for recurrent disease. The final rise in au- 
tologous antibody titers paralleled the development of  dis- 
tant metastases. 
Autologous system UM-SCC-30. This 53-year-old woman 
presented with a T3N 1M0 SCC of the right pyriform sinus. 
Her clinical course is illustrated in Fig. 5. She was initially 
treated with two courses of chemotherapy followed by 
laryngectomy, radical neck dissection and radiation. The 
cell line was established from the primary tumor specimen 
and sera were obtained starting shortly after diagnosis 
while she was receiving chemotherapy. Five months after 
diagnosis she reported pain and dysphagia. Induration of 
the base of  the tongue was noted but no evidence of tumor 
was found at biopsy. Histological confirmation of recurrent 
disease was made 2 months later when positive bronchial 
cytologies and progressive induration of the base of  the 
tongue were noted. She died of progressive disease 
11 months from the first diagnosis. Autologous antibody 
titers in immune complex dissociated sera showed a pro- 
gressive rise (beginning in month 5) that preceded the 
diagnosis of recurrent cancer by several months. Antibody 
reactivity in native sera became detectable rauch later in 
the course of her disease. 
Autologous system UM-SCC-36. This 46-year-old man 
with T2NOM0 SCC of the larynx and false vocal cord was 
treated with a supraglottic laryngectomy and radical dis- 
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Fig. 6. Clinical time course for autologous system UM-SCC-36. The 
changes in autologous antibody titer according to the clinical time course 
of the patient who was the donor of UM-SCC-36. mm, Native serum 
antibody titers; +, immune complex dissociated serum antibody titers 
section of the right side of the heck. The UM-SCC-36 cell 
line was established from the larynx tumor specimen. Col- 
lection of serial serum samples was begun 1 month follow- 
ing surgery. Autologous antibody reactivity was detectable 
in both native and immune complex dissociated sera. Titers 
did not change appreciably over 20 months, during which 
time the patient was clinically free of disease (Fig. 6). 
During this time the patient underwent exploration and 
drainage of an external fistula and abscess, which was not 
felt to be indicative of recurrent disease. Autologous anti- 
body titers were not affected by that episode. The patient is 
still free of disease 5 years later. 
Discussion 
In a previous study, we evaluated the incidence and speci- 
ficity of autologous antibody to SCCHN in both native and 
immune-complex-dissociated sera [23]. Our results were 
similar to findings noted in other tumor systems in that 
autologous antibody reactivity is present in native sera but 
is usually of too low a fiter to permit further evaluation. We 
further noted that dissociation of immune complexes, as 
initially reported by Sjogren et al. [ 18], resulted in higher 
antibody reactivity in treated sera and allowed further eval- 
uation of the host immune response. This report expands 
our previous experience to a total of nine SCCHN autolo- 
gous systems. In all cases autologous antibody reactivity 
was noted to be enhanced following immune complex dis- 
sociation. Our findings suggest that antibody directed 
against autologous tumor cell surface antigens is present in 
a masked form in the sera of the majority of patients with 
SCCHN. 
We have followed autologous antibody reactivity seri- 
ally in six patients to determine the relationship between 
autologous antibody titers and clinical outcome. It appears 
that autologous antibody reactivity to SCCHN does corre- 
late with clinical course, extending previous observations 
made in melanoma [3]. In four of the six autologous sys- 
tems analyzed there were rises in autologous antibody re- 
activity that preceded the diagnosis of recurrence by 1 or 
more months. In UM-SCC-8, -9, -21 and -30 (Figs. 1, 2, 4 
and 5) autologous antibody titers in native and dissociated 
sera began to rise in advance of the diagnosis of recurrent 
disease. The relationship between a rise in autologous anti- 
body titer and recurrence is most clearly seen in UM-SCC- 
30. In that case the rise in autologous antibody titers 
preceded by 4 months the diagnosis of recurrence. Autolo- 
gous antibody titers in acid-dissociated sera rose from 1 : 4 
to a peak of 1:512. Native autologous antibody titers did 
not rise as dramatically but were still noted to increase 
slightly above baseline prior to the diagnosis of recurrence. 
Drops in autologous antibody titers were also noted to 
correlate with clinical course. In UM-SCC-8 decreases in 
autologous antibody titer occurred following surgery or 
radiation. A similar decrease in antibody titer was seen in 
UM-SCC-21 following resection of a recurrent heck mass. 
As the drops in antibody fiter occurred following local 
interventions they might be indicative of a reduction in 
tumor burden. In UM-SCC-8, the initial rise in native and 
dissociated antibody titers coincided with the development 
of a submandibular mass (Fig. 1). On resection the mass 
was noted to be a benign submandibular gland. The rela- 
tionship between autologous antibody titers and this 
benign mass is unclear. It may be that the submandibular 
mass contained an occult focus of SCC that was not appre- 
ciated and its removal eliminated the stimulus for antibody 
production. Alternatively, it is possible that a decline in 
antibody fiter may occur following any surgical interven- 
tion. No changes in autologous antibody titers were noted 
following chemotherapy (UM-SCC-30) or the develop- 
ment of an abscess (UM-SCC-36). The absence of any 
effect of chemotherapy on autologous antibody titers is 
consistent with previous observations we made in melano- 
ma [19]. 
In two cases increases in antibody titers did not appear 
to correlate with clinical course. In both cases (UM-SCC- 
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17 and UM-SCC-36), the patients have been long-term 
survivors and are alive and clinically free of disease at this 
time. In the case of UM-SCC-17 (Fig. 3) both native and 
dissociated autologous antibody titers were high during the 
2 first postoperative years. The titers then fell with no 
apparent change in the patient's clinical course and then 
began to rise again, also without a change in clinical status, 
26 months following resection of her tumor. While the 
nature of this patient' s disease (i. e. recurrence immediately 
after radiotherapy and extension through the laryngeal car- 
tilage into the adjacent soft tissue) makes a recurrence very 
likely, she has remained free of disease for more than 
7 years. In the case of UM-SCC-36 there was also no clear 
association of antibody titer with clinical course. Autolo- 
gous antibody titers were relatively constant over a 2-year 
period following surgery. This case is reminiscent of the 
AH/SK-MEL-13 system analyzed by Shiku et al. [16]. In 
that system autologous antibody titers did not change over 
time nor did the disease recur [2]. 
The primary impetus for these studies has been the 
observation that patients with SCCHN and other malignan- 
cies produce an antibody directed against their own tumor 
[11, 15, 24]. Because the antigens detected by these anti- 
bodies are, by definition, immunogenic to the host, further 
analysis is of interest. It is premature to state that these 
observations can be extrapolated into a clinically relevant 
assay. Two instances were noted in which antibody titers 
did not correlate with clinical course. It is intriguing that 
these two cases occurred in long-term survivors and sug- 
gests that other factors may be involved. Studies involving 
larger numbers of patients may help resolve this. However, 
the fact that rises and falls in autologous antibody reactiv- 
ity could, in some instances, be correlated with the clinical 
course confirms studies performed in a separate tumor 
system [19] and is the first time this observation has been 
made in squamous cell carcinoma. 
The specificity analysis performed on the six autolo- 
gous systems reported here indicated that the antigen(s) 
being detected after acid dissociation/ultrafiltration have 
an identical distribution. Antibody reactivity could be ab- 
sorbed by seven of seven SCCHN cell lines and two of two 
melanoma cell lines. No reactivity could be detected by 
absorption with other neoplastic and normal cells. This 
distribution of reactivity is consistent with a class II tumor- 
associated antigen as described by Shiku et al. [16, 17] in 
studies of melanoma (those which are shared among 
tumors of a similar histotype or ontogeny and infrequently 
found in non-neoplastic cells). The cross-reactivity with 
melanoma cells, seen in the present studies, is noteworthy. 
In previous studies of melanoma and SCCHN patients we 
have noted a similar range of antibody reactivity [21-23].  
While specificity analysis of the antigen detected by autol- 
ogous antibody allows for determination of the distribution 
of the antigen, it is, at best, limited. A major drawback in 
this approach is that it seeks to define a "null hypothesis". 
It can never be entirely proven that the antigen described 
will not be found on an untested cell line. Determination of 
the nature of the antigens detected by autologous antibody 
will have to await ongoing immunochemical analysis. 
The nature of the relationship between the autologous 
antibody response and the host/tumor interaction remains 
to be determined. It is unknown whether the antigens and 
antibodies detected in this study are an indicator of the 
host's response to malignant cells or are somehow in- 
volved in the modulation of that response. Immune com- 
plexes and tumor-associated antigens have been implicated 
in immunosuppression [1, 14]. These results demonstrate 
that serial autologous antibody studies can be correlated 
with clinical course and may provide a means by which the 
physiological relevance of the autologous immune re- 
sponse to malignant disease can be studied. 
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